Hispanic Patients with Myeloma Present Earlier, More Likely to Have Advanced Disease

Results from a large analysis of individuals of Hispanic ethnicity with multiple myeloma (MM) found showed unique disease characteristics in this population, such as earlier presentation and higher rates of renal dysfunction, compared to other ethnic and racial groups.

A research team from the Albert Einstein College of Medicine in New York conducted a single-center study comparing clinical characteristics and overall survival of Hispanic patients with MM compared with non-Hispanic white (NHW) and non-Hispanic Black (NHB) patients. A total of 939 participants were enrolled: 281 Hispanic, 489 NHB, and 169 NHW. A validation cohort was derived using data from the Connect MM Registry, a large US multicenter study of newly diagnosed MM patients.

The investigators found that Hispanic patients had an overall higher incidence of MM compared with NHW. The median age of disease presentation was also 5 years younger in Hispanic compared with NHW patients (65 years vs. 70 years, respectively). Hispanic patients also had increased odds of presentation with renal dysfunction, or an estimated glomerular filtration rate < 30 mL/min. Overall, Hispanic patients had higher proportion of Revised International Staging System (R-ISS) stage I disease compared with the other study groups (P=0.03).

There was no difference in cytogenetics between the three participant groups. After adjustment, only high-risk disease and first-line therapy response was significantly associated with survival in Hispanic patients.

“In this first and largest analysis of MM in Hispanics, we found that Hispanics present at a younger age, have a higher incidence of renal dysfunction, and have low R-ISS stage disease at presentation. With equal access to therapy, Hispanics have survival similar to NHW/NHB,” the researchers concluded.

This study was published in Clinical Myeloma, Lymphoma, & Leukemia.